Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis.
Jun ItakuraMasayuki KurosakiHiroko SetoyamaTetsuro SimakamiNoriko OzaMasaaki KorenagaMotohiko TanakaTakuji TorimuraNaoya SakamotoNobuyuki EnomotoYoshiyuki UenoNorifumi KawadaShuichi KanekoShuhei NishiguchiKazuaki ChayamaJunko TanakaNamiki IzumiTatsuya KantoPublished in: Journal of gastroenterology (2021)
The APRI and FIB-4 may serve as a transition indicator of liver fibrosis in anti-viral treatment-naïve patients with chronic hepatitis C.